GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSK) is expected to announce its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $8.2086 billion for the quarter. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Price Performance

Shares of GSK opened at $43.88 on Tuesday. The company has a market capitalization of $89.19 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 1.95 and a beta of 0.53. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $46.87. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The business’s 50-day moving average is $41.62 and its 200-day moving average is $39.44.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were given a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Friday, August 15th. GSK’s dividend payout ratio (DPR) is presently 78.24%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GSK. SkyView Investment Advisors LLC bought a new position in shares of GSK in the second quarter valued at about $303,000. Captrust Financial Advisors raised its holdings in shares of GSK by 11.0% in the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock valued at $3,267,000 after buying an additional 8,432 shares during the last quarter. IHT Wealth Management LLC raised its holdings in shares of GSK by 12.1% in the second quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock valued at $566,000 after buying an additional 1,589 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of GSK by 28.2% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after buying an additional 26,685 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of GSK by 1.2% in the second quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock valued at $15,444,000 after buying an additional 4,855 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a research report on Monday. Weiss Ratings reissued a “hold (c)” rating on shares of GSK in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.